Navigation Links
Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion
Date:3/18/2008

DEERFIELD, Ill., March 18 /PRNewswire-FirstCall/ -- Baxter International Inc. (NYSE: BAX) announced today that its Board of Directors has approved the repurchase of an additional $2 billion of the company's common stock to be executed upon completion of the company's existing share repurchase authorization.

Baxter has less than $700 million of remaining authorization under its previous $2 billion share repurchase program that was authorized in March 2007. Shares will be repurchased in the open market at times and amounts determined by management based on its evaluation of market conditions and other factors.

In 2007, Baxter returned more than $2.5 billion to shareholders through both share repurchases and dividends. The company repurchased 34 million shares of common stock, for approximately $1.9 billion, and paid dividends totaling $704 million.

"We remain confident in our ongoing ability to generate strong cash flows," said Robert M. Davis, chief financial officer. "We expect to return significant value to shareholders through a disciplined approach to capital allocation and financial management, while accelerating our investment in R&D and new business development opportunities that position us for future growth."

Baxter International Inc., through its subsidiaries, assists healthcare professionals and their patients with the treatment of complex medical conditions, including hemophilia, immune disorders, cancer, infectious diseases, kidney disease, trauma and other conditions. The company applies its expertise in medical devices, pharmaceuticals and biotechnology to make a meaningful difference in patients' lives.

This release includes forward-looking statements concerning the company's expected cash flows, investments in R&D, accelerating business development activities and share repurchases and investments. The statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those in the forward-looking statements: the company's ability to identify and execute on business development and R&D opportunities; continued strength in the company's financial position, including cash flows; alternative uses of funds including, but not limited to dividends, business development transactions, and other investments in the company's businesses; and other risks identified in the company's most recent filing on Form 10-K and other SEC filings, all of which are available on the company's website. The company does not undertake to update its forward-looking statements.


'/>"/>
SOURCE Baxter International Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets
2. KGI Elects Three New Members to Board of Trustees
3. Ralf Rosskamp, M.D. Joins Biodels Scientific Advisory Board
4. DOV Pharmaceutical, Inc. Begins Trading on OTC Bulletin Board
5. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
6. BioLife Solutions Expands Scientific Advisory Board
7. NeurogesX Appoints New Director to the Board
8. Genstar Names Michael Hurt to Its Strategic Advisory Board
9. Boston Scientific Announces Election of Ray Elliott to Its Board of Directors
10. Bruce Pasternack Elected to Codexis Board
11. Interleukin Genetics Announces Management and Board Appointments
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... June 27, 2016  Sequenom, Inc. (NASDAQ: ... healthier lives through the development of innovative products and ... the United States denied its petition ... claims of Sequenom,s U.S. Patent No. 6,258,540 (",540 Patent") ... established by the Supreme Court,s Mayo Collaborative Services v. ...
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... ... 24, 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona ... or pleural mesothelioma. Their findings are the subject of a new article on the ... are signposts in the blood, lung fluid or tissue of mesothelioma patients that can ...
(Date:6/23/2016)... A person commits a crime, and the detective ... the criminal down. An outbreak of foodborne illness ... (FDA) uses DNA evidence to track down the bacteria that ... It,s not. The FDA has increasingly used a complex, cutting-edge ... illnesses. Put as simply as possible, whole genome sequencing is ...
Breaking Biology Technology:
(Date:6/22/2016)... , June 22, 2016   Acuant ... and verification solutions, has partnered with RightCrowd ... solutions for Visitor Management, Self-Service Kiosks and ... products that add functional enhancements to existing ... corporations and venues with an automated ID ...
(Date:6/16/2016)... 16, 2016 The global ... to reach USD 1.83 billion by 2024, according ... Inc. Technological proliferation and increasing demand in commercial ... to drive the market growth.      ... The development of advanced multimodal techniques for biometric ...
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
Breaking Biology News(10 mins):